Brief Behavioral Intervention for Comorbid Migraine and Depression (ACT-IM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01775852
Recruitment Status : Completed
First Posted : January 25, 2013
Results First Posted : September 17, 2015
Last Update Posted : February 22, 2018
Information provided by (Responsible Party):
Lilian N. Dindo, University of Iowa

January 9, 2012
January 25, 2013
June 4, 2015
September 17, 2015
February 22, 2018
August 2010
May 2012   (Final data collection date for primary outcome measure)
Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up [ Time Frame: 12 week change from baseline ]

The HAM-D is a structured clinical interview for assessing depression severity. Outcome measure will be change from Baseline in Hamilton Depression Rating Scale at 12 week (3 month) follow-up from baseline.

Measure is scored by adding individual items and attaining an overall severity score. Scores range from 0 to 53, with higher values signifying a higher level of depression severity (and thus a worse outcome). A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.

HAM-D [ Time Frame: 12 weeks ]
The HAM-D is a structured clinical interview for depression severity.Change from Baseline in Hamilton Depression Rating Scale at 12 weeks
Complete list of historical versions of study NCT01775852 on Archive Site
  • Mean Change Score in HDI (Headache Disability Inventory) From Baseline to 12 Weeks. [ Time Frame: 12 week change from baseline ]

    The HDI is useful in assessing the impact of headache, and its treatment, on daily living. 25 self-report items are rated with answers as "Yes" (4 points), "Sometimes" (2 Points), and "No" (0 points). All items are then added together to create an overall score which can range from 0 (no impact), to 100 (severe impact) of headache on daily life.

    A 29 point change (95% confidence interval) or greater in the total score from test to retest must occur before the change can be attributed to treatment effects.

  • Mean Change on Short Form Health Survey (SF-36) From Baseline to 12 Week Follow-up. [ Time Frame: Change at 12 week follow-up from baseline ]

    The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.

    The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

  • Mean Change of World Health Organization Disability Assessment (WHO-DAS) From Baseline to 12-week Follow up. [ Time Frame: Change at 12 week follow-up from baseline ]

    The WHODAS contains 36 items on functioning and disability with a recall period of 30 days covering 7 domains: Understanding and Communicating (6 items), Getting around (5 items), Self-care (4 items), Getting along with others (5 items), Life activities: household (4 items), Life activities: work/school (4 items), and Participation in society (8 items). Response options go from 1 (no difficulty) to 5 (extreme difficulty or can not do).

    WHODAS domain scores are computed for each domain by adding the item responses together. A global score is then computed by summing all domains together, and transforming them into a range from 0 to 100, with higher scores indicating higher levels of disability (0= no disability, 100= full disability).

  • HDI (Headache Disability Inventory) [ Time Frame: 12 weeks ]

    This is a self-report questionnaire used to determine the effectiveness of a management strategy over time.

    Change from Baseline in HDI at 12 weeks

  • SF-36 [ Time Frame: 12 week follow-up ]
    This is a self-report questionnaire used to measure physical and emotional health problems.
  • WHO-DAS [ Time Frame: 12 week follow-up ]
    This is a self-report questionnaire that measures difficulties due to physical and mental health conditions.
  • Structured Clinical Interview for DSM-IV Disorders (SCID-IV) [ Time Frame: 12-week follow-up ]
    Semi-structured clinical interview for Depression
Not Provided
Not Provided
Brief Behavioral Intervention for Comorbid Migraine and Depression
Brief, Behavioral Intervention of ACT & Illness Management for Comorbid Migraine and Depression
The purpose of this research study is to examine whether a one-day group workshop, integrating principles from Acceptance and Commitment Therapy with Migraine Education, will result in improvements in depressive symptoms and functioning impairment in patients with comorbid migraine and depression.

Migraine affects approximately 35 million US residents (Bigal & Lipton, 2009) and is associated with excruciating headache and marked functional impairment. Epidemiological and clinical research has shown that people with migraine suffer from psychiatric disorders at a disproportionately higher rate than individuals without. Depression, in particular, is 3-5 times more common in migraine patients than in non-migraineurs. The comorbidity of depression and migraine is a major health concern as it results in poorer prognosis, remission rate, and response to treatment. In addition, an increase in the severity of migraine is associated with a parallel rise in the severity and treatment resistance of comorbid depression.

Recent research in behavioral medicine suggests that the pain experience per se does not necessarily lead to depression or impairment. Instead, it is the preoccupation with avoiding aversive stimuli associated with pain (i.e., activities, places, movements) that results in depression and disability (e.g., McCracken et al., 2005). Therefore, given that patients with migraine and/or depression exhibit more avoidance behaviors and lower activity levels than healthy controls (e.g., Stronks et al., 2004), an intervention aimed at optimizing willingness and acceptance and minimizing behavioral avoidance may be beneficial at improving both their depression and migraine and, consequently, their daily functioning.

Acceptance and Commitment Therapy (ACT) is an empirically based behavioral therapy that incorporates acceptance and mindfulness strategies with behavioral change strategies. ACT (in group and in individual settings) is effective in treating psychiatric disorders commonly associated with migraine, including depression, anxiety, and stress (e.g., Hayes, 2001) as well as chronic illnesses like pain and diabetes (Dahl et al, 2004; Gregg et al., 2006). Importantly, ACT resulted in positive long-term outcomes even when presented in brief form. For example, a two-day ACT workshop, in a group setting, led to improvements in depression and distress experienced by parents of children diagnosed with autism and these gains were retained 3 months later. Parents also exhibited a reduction in avoidance behaviors (Blackledge & Hayes, 2006).

Not Applicable
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Migraine
  • Depression
Behavioral: ACT-IM
1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
Other Names:
  • Acceptance and Commitment Therapy
  • Illness Management
  • Active Comparator: ACT-IM
    The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
    Intervention: Behavioral: ACT-IM
  • No Intervention: Waitlist/Treatment as Usual
    The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2013
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18-75
  • 4 to 12 migraines in the previous month
  • Major or Minor Depression
  • English-speaking

Exclusion Criteria:

  • Patients with other major psychiatric disorders such as bipolor disorder, schizophrenia, and current illicit drug use.
  • Patients with major head injuries.
  • Patients with serious medical illnesses.
  • Patients who have started a new medication in previous 4 weeks or plan on starting a new medication in the next 4 weeks.
  • Patients expressing significant suicidal ideation.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
ICTS-01 ( Other Grant/Funding Number: University of Iowa, ICTS )
Not Provided
Not Provided
Lilian N. Dindo, University of Iowa
Lilian N. Dindo
Not Provided
Principal Investigator: Lilian Dindo, PhD University of Iowa
University of Iowa
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP